1. Institute of Experimental Medicine, St. Petersburg, Russia; St Petersburg University, St. Petersburg, Russia 2. Institute of Experimental Medicine, St. Petersburg, Russia 3. Institute of Experimental Medicine, St. Petersburg, Russia; Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, St. Petersburg, Russia
The tested drug cramizol exhibits lipid-lowering and anti-atherogenic effects. Cramizol reduces blood cholesterol and triglycerides. It also increases HDL and reduces the atherogenic index in rats with the chronic dyslipidemia model induced by a hypercholesterol diet. Cramizol is effective as a hypolipidemic agent and its efficiency is comparable with the reference drug, phenofibrate. Cramizol increases expression of the ApoA1 and ApoC2 genes, and also reduces expression of the Scarb1 gene in rats with experimentally induced hyperlipidemia. These mechanisms could be the basis of its hypolipidemic and anti-atherogenic actions.
Lizunov A.V., Okunevich I.V., Lebedev A.A., Bychkov E.R., Piotrovskiy L.B., Shabanov P.D. (2020) Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model. Biomeditsinskaya Khimiya, 66(4), 326-331.
Lizunov A.V. et al. Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model // Biomeditsinskaya Khimiya. - 2020. - V. 66. -N 4. - P. 326-331.
Lizunov A.V. et al., "Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model." Biomeditsinskaya Khimiya 66.4 (2020): 326-331.
Lizunov, A. V., Okunevich, I. V., Lebedev, A. A., Bychkov, E. R., Piotrovskiy, L. B., Shabanov, P. D. (2020). Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model. Biomeditsinskaya Khimiya, 66(4), 326-331.
